Biblio

2023
Heitmann JS, Schlenk RF, Dörfel D, Kayser S, Döhner K, Heuser M, Thol F, Kapp-Schwoerer S, Labrenz J, Edelmann D, et al. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. J Hematol Oncol. 2023;16(1):96.
Lightner AL, Otero-Pineiro A, Reese J, Ream J, Nachand D, Adams AC, VanDenBossche A, Kurowski JA. A Phase I Study of Ex Vivo Expanded Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Pediatric Perianal Fistulizing Crohn's Disease. Inflamm Bowel Dis. 2023.
Wang J, Sanati F, Firoozmand A, Fu P, Kolk M, Reese-Koc J, de Lima M, Boughan K, Cooper B, Caimi P, et al. Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens. Front Oncol. 2023;13:1186532.
Phan TG, Lim R, Chan ST, McDonald H, Gan P-Y, Zhang SR, Arce LJBarreto, Vuong J, Thirugnanachandran T, Clissold B, et al. Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT). Front Neurosci. 2023;17:1153231.
Lightner AL, Reese J, Ream J, Nachand D, Jia X, Dadgar N, Steele SR, Hull T. A Phase IB/IIA Study of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease. Dis Colon Rectum. 2023.
Gholami F, Farahani RHamidi, Rahjerdi AKarimi, Ahi M, Sheidaei A, Gohari K, Rahimi Z, Ansarifar A, Basiri P, Moradi M, et al. Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years. BMC Infect Dis. 2023;23(1):118.
Ness DB, Pooler DB, Ades S, Highhouse BJ, Labrie BM, Zhou J, Gui J, Lewis LD, Ernstoff MS. A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma. Cancer Med. 2023.
Ikoma Y, Nakamura N, Kitagawa J, Miwa T, Takada E, Matsumoto T, Shibata Y, Nakamura H, Kanemura N, Kasahara S, et al. A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma. Hematol Oncol. 2023.
Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk A-C, Wehr C, Maas-Bauer K, Melchinger W, Haring E, et al. Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response. Br J Haematol. 2023.
O'Shea AE, Clifton GT, Qiao N, Heckman-Stoddard BM, Wojtowicz M, Dimond E, Bedrosian I, Weber D, Garber JE, Husband A, et al. Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ. Cancer Prev Res (Phila). 2023;16(6):333-341.
Zhang Q, Deng K, Liu M, Yang S, Xu W, Feng T, Jie M, Liu Z, Sheng X, Chen H, et al. Phase separation of BuGZ regulates gut regeneration and aging through interaction with mA regulators. Nat Commun. 2023;14(1):6700.
Zhao J, Wang X, Zhu J, Chukwudi C, Finebaum A, Zhang J, Yang S, He S, Saeidi N. PhaseFIT: live-organoid phase-fluorescent image transformation via generative AI. Light Sci Appl. 2023;12(1):297.
H Diaz-Ardila N, Gujas B, Wang Q, Moret B, Hardtke CS. pH-dependent CLE peptide perception permits phloem differentiation in Arabidopsis roots. Curr Biol. 2023.
Li J, Chi J, Yang Y, Song Z, Yang Y, Zhou X, Liu Y, Zhao Y. PHDs-seq: a large-scale phenotypic screening method for drug discovery through parallel multi-readout quantification. Cell Regen. 2023;12(1):22.
Safarpour A, Ebrahimi M, Fazeli SAbolhassan, Amoozegar MAli. A phenol amine molecule from Salinivenus iranica acts as the inhibitor of cancer stem cells in breast cancer cell lines. Sci Rep. 2023;13(1):12669.
Saghati S, Avci ÇBiray, Hassani A, Kerdar SNazif, Amini H, Saghebasl S, Mahdipour M, Banimohamad-Shotorbani B, Namjoo ARezaei, Abrbekoh FNazary, et al. Phenolated alginate hydrogel induced osteogenic properties of mesenchymal stem cells via Wnt signaling pathway. Int J Biol Macromol. 2023:127209.
Nazam N, Jabir NR, Ahmad I, Alharthy SA, Khan MShahnawaz, Ayub R, Tabrez S. Phenolic Acids-Mediated Regulation of Molecular Targets in Ovarian Cancer: Current Understanding and Future Perspectives. Pharmaceuticals (Basel). 2023;16(2).
Andonova T, Muhovski Y, Slavov I, Vrancheva R, Georgiev V, Apostolova E, Naimov S, Mladenov R, Pavlov A, Dimitrova-Dyulgerova I. Phenolic Profile, Antioxidant and DNA-Protective Capacity, and Microscopic Characters of Aerial Substances. Plants (Basel). 2023;12(4).
Mokhtar N, Karunakaran T, Santhanam R, Bakar MHafizi Abu, Jong VYi Mian. Phenolics and triterpenoids from stem bark of (Whitmore) P. F. Stevens and their cytotoxic activities. Nat Prod Res. 2023:1-6.
Muroke V, Jalanko M, Ruotsalainen S, Perola M, Helle E, Sinisalo J. Phenotype of ASDs Associated With 4p16 Risk Locus and Novel Genome-Wide Associations of ASD Patients in the Finnish Population. Circ Genom Precis Med. 2023:e004070.
Persico I, Fiscarelli I, Pelle A, Faleschini M, Pasini B, Savoia A, Bottega R. Phenotype reversion as "natural gene therapy" in Fanconi anemia by a gene conversion event. Front Genet. 2023;14:1240758.
Papaioannou VE, Behringer RR. Phenotypic Analysis of Dominant Mutant Effects in Mice. Cold Spring Harb Protoc. 2023.
Verta R, Saccu G, Tanzi A, Grange C, Buono L, Fagoonee S, Deregibus MChiara, Camussi G, Scalabrin S, Nuzzi R, et al. Phenotypic and functional characterization of aqueous humor derived extracellular vesicles. Exp Eye Res. 2023:109393.
Hekmatshoar Y, Gurel AKaradag, Ozkan T, Saadat YRahbar, Koc A, Karabay AZeynep, Bozkurt S, Sunguroglu A. Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line. Adv Med Sci. 2023;68(2):238-248.
Kobayashi K, Takemura RDeja, Miyamae J, Mitsui I, Murakami K, Kutara K, Saeki K, Kanda T, Okamura Y, Sugiyama A. Phenotypic and molecular characterization of novel pulmonary adenocarcinoma cell lines established from a dog. Sci Rep. 2023;13(1):16823.

Pages